Drug intelligence / Profile preview

ranibizumab + levosulpiride

Development stage: Unknown
Lead developer: Genentech
Modality: Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Ophthalmic, Oral, Intramuscular

Overview

This is a combination therapy consisting of ranibizumab and levosulpiride. Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment that targets vascular endothelial growth factor A (VEGF-A), used to treat various ocular disorders including diabetic macular edema and age-related macular degeneration. Levosulpiride is a selective dopamine D2 receptor antagonist and serotonin 5-HT4 receptor agonist used for psychiatric conditions, depression, and gastrointestinal disorders. The combination is being investigated for potential synergistic effects in treating retinal conditions.

Targets

VEGFA (Vascular endothelial growth factor A)DRD2 (Dopamine D2 Receptor)HTR4 (5-Hydroxytryptamine receptor 4)

Beyond the preview

Go deeper on ranibizumab + levosulpiride.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ranibizumab + levosulpiride.

Explore the full profile